Evidence map›Paper›PMID 31046700›Full record

Trial reportBMC gastroenterology2019

Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China.

Jian Sun, Huiguo Ding, Guofeng Chen, Guiqiang Wang, Lai Wei, Jiming Zhang, Qing Xie, Mobin Wan, Hong Tang, Shijun Chen and 14 more

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. [Analysis of liver histological characteristics and clinically related factors in patients with inactive HBsAg carriers].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 19 institutions in 1 country.

Jian SunState Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Huiguo DingBeijing You'an Hospital, Capital Medical University, No. 8, You An Men Wai Street, Fengtai District, Beijing, 100069, China.
Guofeng ChenBeijing 302 Hospital, No. 100, Xi Si Huan Zhong Lu, Beijing, 100039, China.
Guiqiang WangPeking University First Hospital, No. 8, Xicheng Xishiku Street, Beijing, 100034, China.
Lai WeiPeking University People's Hospital, No. 11 Xizhimen South Street, Beijing, 100044, China.
Jiming ZhangHuashan Hospital, Fudan University, No. 12, Middle Wurumuqi Rd, Shanghai, 200040, China.
Qing XieShanghai Ruijin Hospital Affiliated Shanghai Jiao Tong University, No. 197, Ruijiner Rd, Shanghai, 200025, China.
Mobin WanShanghai Changhai Hospital, No. 174, Changhai Rd, Shanghai, 200433, China.
Hong TangHuaxi Hospital of Sichuan University, No. 37, Guo Xue Xiang, Chengdu, 610041, China.
Shijun ChenJinan Infectious Disease Hospital, No. 173, Jingshi Rd, Jinan, 250021, China.
Zhiliang GaoThe Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Rd, Guangzhou, 510630, China.
Yuming WangSouthwest Hospital Affiliated Third Military Medical University, No. 29, Gao Tan Yan Zhengjie, Shapingba, Chongqing, 400038, China.
Dazhi ZhangDepartment of Infectious Disease, No. 2 Affiliated Hospital of Chongqing Medical University, No 74, Lingjiang Road, Yuzhong district, Chongqing, China.
Wenxiang HuangNo. 1 Hospital of Chongqing Medical University, No. 1, Youyi Rd, Chongqing, 400016, China.
Jifang ShengThe First Affiliated Hospital of Zhejiang University Medical College, No. 79, Qingchun Rd, Hangzhou, 310003, China.
Qin NingTongji Hospital Affiliated Tongji Medical College of Huazhong University of Science & Technology, No. 1095, Jiefang Avenue, Wuhan, 430030, China.
Dongliang YangDepartment of Infectious Disease, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, 1277#, Jiefang Avenue, Wuhan, 430022, China.
Jian LuShenzhen Third People's Hospital, Bulan Road 29, Longgong, Shenzhen, 518112, People's Republic of China.
Chen PanFuzhou Infectious Disease Hospital, No. 312, Xihong Rd., Gulou District, Fuzhou, 350025, China.
Yuxiu YangHenan Provincial People's Hospital, No. 7, Weiwu Rd, Zhengzhou, 450003, China.
Jue WangMSD China, Building A, Headquarters Park, Phase 2, 1582 Gumei Road Xuhui District, Shanghai, 200233, China.
Chuanzhen SunMSD China, Building A, Headquarters Park, Phase 2, 1582 Gumei Road Xuhui District, Shanghai, 200233, China.
Qixin WangMSD China, Building A, Headquarters Park, Phase 2, 1582 Gumei Road Xuhui District, Shanghai, 200233, China.
Jinlin HouState Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China. jlhousmu@163.com.
Huazhong University of Science and Technology · CNNanfang Hospital · CN302 Military Hospital of China · CNArmy Medical University · CNBeijing YouAn Hospital · CNChanghai Hospital · CNChinese Journal of Integrated Traditional and Western Medicine · CNChongqing Medical University · CNFuzhou Pulmonary Hospital of Fujian · CNHenan Provincial People's Hospital · CNHuashan Hospital · CNJinan Infectious Disease Hospital · CNPeking University · CNPeking University First Hospital · CNShanghai Jiao Tong University · CNShenzhen Third People’s Hospital · CNSichuan University · CNThird Affiliated Hospital of Sun Yat-sen University · CNZhejiang University · CN

Funding

Merck Sharp & Dohme, Shanghai, China N/A
6 · The paper itself

Abstract

backgroundPegylated interferon (PEG-IFN) alfa-2b is recommended for chronic hepatitis B (CHB). We aimed to investigate the sustainability of off-treatment responses among Chinese HBeAg-positive CHB patients treated with PEG-IFN alfa-2b from a randomized trial.

methodsEligible Chinese patients (n = 322) were followed up by one visit after a median of 6 years (LTFU) following their participation in a randomized trial evaluating the efficacy of three PEG-IFN alfa-2b dosing regimens (1.0 or 1.5 μg/kg/wk. 24 weeks or 1.5 μg/kg/wk. 48 weeks). Primary endpoints at the LTFU were sustained SR and CR (SR/CR at the end of original study [EOS] and at the LTFU). SR was defined as HBeAg loss and seroconversion to anti-HBe and CR as HBeAg loss and seroconversion to anti-HBe and HBV-DNA < 2000 IU/mL.

resultsThe proportions of patients achieving sustained SR among patients who had SR at EOS were high in three treatment groups (61.9, 65.5, 76.5%, respectively, p = 0.46); treatment with PEG-IFN alfa-2b 1.5 μg/kg/wk. 48 weeks had the highest proportion of a sustained CR among patients who had CR at EOS (75.0%, p = 0.05). A considerable number of patients achieved sustained SR (18.2-29.9%) and sustained CR (14.8-18.3%) after EOS despite no further NA treatment. At the LTFU, rates of SR and CR were less than 70.0 and 50.0%, respectively, among all enrolled patients regardless of additional nucleos(t)ide analogs before the LTFU.

conclusionsPEG IFN alfa-2b therapy had considerable off-treatment sustainability in Chinese HBeAg positive chronic hepatitis B patients with serological and complete responses.

Indexed as

Sustained Virologic ResponseAdultAntiviral AgentsChinaFemaleFollow-Up StudiesHepatitis B, ChronicHepatitis B e AntigensHumansInterferon-alphaInterferon alpha-2MalePolyethylene GlycolsRecombinant ProteinsYoung AdultAntiviral AgentsHepatitis B e AntigensInterferon-alphaInterferon alpha-2peginterferon alfa-2bPolyethylene GlycolsRecombinant ProteinsChronic hepatitis BLong-term follow-upPeg-interferonSustained combined clinical responseSustained serological response

Identifiers

PMID31046700
PMCPMC6498535
OpenAlexW2947024826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.